Core Insights - BridgeBio Pharma, Inc. announced the presentation of long-term efficacy and safety data for acoramidis in patients with ATTR-CM at the ACC Annual Scientific Sessions & Expo [1] - The company will present a late-breaking oral presentation and three posters detailing additional findings from the open-label extension trial [2] Group 1: Presentation Details - The late-breaking oral presentation titled "Long-Term Survival Benefits and Disease Stabilization with Acoramidis in Patients with ATTR-CM" will be presented by Dr. Prem Soman on March 30, 2026 [2] - Three posters will cover various aspects of acoramidis treatment, including its effects on serum transthyretin concentrations and health status related to heart failure [2] Group 2: Product Information - Attruby™ (acoramidis) is indicated for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM) in adults, aiming to reduce cardiovascular death and related hospitalizations [3] Group 3: Safety Information - Adverse reactions reported for Attruby include diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4% for placebo), with most being mild and resolving without discontinuation [4]

Financial Position - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $91.5 million, a decrease from $122.6 million as of December 31, 2024 [6] - The company used $39.6 million in operating activities during 2025, which included one-time payments related to restructuring efforts [6] Revenue and Financial Performance - Total revenue for the year ended December 31, 2025, was $14.1 million, up from $6.2 million in 2024, primarily due to the recognition of previously deferred revenue from a partnership with Qilu Pharmaceutical [7] - The company reported a net loss of $33.5 million for 2025, compared to a net loss of $69.9 million in 2024, indicating improved financial performance [10] Operating Expenses - Research and development expenses decreased to $25.2 million in 2025 from $54.0 million in 2024, attributed to cost-saving measures and a focus on advancing clinical development [8] - General and administrative expenses also fell to $15.9 million in 2025 from $22.1 million in 2024, reflecting cost-cutting efforts [9] Clinical Developments - Two additional patients from Phase 2a clinical trials of imdusiran achieved functional cure for chronic hepatitis B (cHBV), bringing the total to ten patients [2][4] - Imdusiran is designed to reduce all hepatitis B viral proteins and antigens, with clinical trials showing it to be generally safe and well-tolerated [17] Legal and Settlement Updates - The company entered a settlement agreement with Moderna, resulting in a $950 million upfront payment and a potential additional $1.3 billion contingent payment [4] - The company is actively involved in ongoing litigation to protect its intellectual property related to lipid nanoparticle technology against Pfizer/BioNTech [4] Future Outlook - The company is evaluating a potential return of capital to shareholders in the third quarter of 2026, following the receipt of its portion of the noncontingent settlement payment from Moderna [5]

Core Insights - Q-Gold Resources Ltd. has announced significant management changes to enhance its leadership as it advances the Quartz Mountain Gold Project in Oregon, with Peter Tagliamonte appointed as Executive Chairman and Jamsheed Mehta as President [1][3][12] Management Changes - Stan Bharti transitions to a strategic advisory role after successfully positioning the company for its next development phase [10][11] - Jamsheed Mehta, with over 35 years of capital markets experience, is appointed as President, bringing extensive knowledge of the mining sector [12][14] - Stephen Woodhead is appointed as Chief Financial Officer, contributing over 30 years of experience in the resource sector [15][16] - Mark Albertson joins as Director of Government and Community Relations, leveraging his local expertise to foster community relations [18][22] Project Development - The Quartz Mountain Gold Project is progressing well, with a preliminary economic assessment (PEA) expected to be released in April 2026, anticipated to confirm the project's economic viability [2][4][5] - The project is expected to create significant employment and investment opportunities in the Lakeview and Bly region of Lake County, Oregon [5] - Exploration programs are planned for summer and fall 2026 at both Quartz Mountain and Angel's Camp, aiming to expand the resource base [6] Exploration Initiatives - A comprehensive exploration program is set to begin at the Mine Centre Gold Project in Ontario, Canada, during summer and fall 2026 [7] - The focus will be on understanding gold-bearing quartz vein systems and defining new mineralized zones [7] Project Background - The Quartz Mountain Gold Project, acquired from Alamos Gold in Q4 2025, is located in a historically productive gold district with excellent infrastructure access [28] - The project has an established mineral resource estimate, including approximately 1,543,000 ounces of gold at a grade of 0.96 g/t and 2,049,000 ounces of silver at a grade of 1.27 g/t [34]

Core Viewpoint - Aptose Biosciences Inc. shareholders are recommended to vote "FOR" the proposed arrangement with Hanmi Pharmaceutical Co. Ltd. to acquire all outstanding common shares not currently owned by Hanmi or its affiliates [1][8] Group 1: Arrangement and Continuance - Glass Lewis, an independent proxy advisory firm, has recommended that shareholders approve the arrangement with Hanmi [1] - The company is transitioning from being governed under the Canada Business Corporations Act to the Business Corporations Act (Alberta) [2] - The completion of the transaction is subject to customary closing conditions, including court approval and approval from the TSX [8] Group 2: Meeting Details - A special meeting of shareholders has been reconvened for March 31, 2026, at 11:00 a.m. (EST) to seek approval for the arrangement and continuance [4] - The meeting will be held virtually via live audio webcast [4] - Shareholders are encouraged to submit their proxies ahead of the voting deadline on March 27, 2026, at 11:00 a.m. (EST) [3][7] Group 3: Proxy Statement and Voting Assistance - Aptose has filed a definitive proxy statement with the SEC for the reconvened meeting, which has been mailed to all shareholders [5] - Shareholders who have questions or need voting assistance can contact Morrow Sodali (Canada) Ltd. [10]

Core Insights - Lexicon Pharmaceuticals and Novo Nordisk are collaborating on LX9851, an oral non-incretin candidate for obesity and metabolic disorders, with Novo Nordisk initiating a Phase 1 study [1][4] - Lexicon has received a second $10 million milestone payment from Novo Nordisk and is eligible for up to $1 billion in total payments, including royalties on net sales [3] Group 1: LX9851 Development - LX9851 is a first-in-class oral small molecule inhibitor of Acyl CoA Synthetase 5 (ACSL5), which regulates fat accumulation and energy balance [5] - The Phase 1 study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in 96 participants with overweight or obesity, expected to complete in Q1 2027 [4] Group 2: Financial Aspects - Lexicon is eligible for a total of three $10 million milestone payments, with the second payment received in 2026 following initial dosing in the Phase 1 study [3] - The collaboration agreement allows Lexicon to receive up to $1 billion in upfront and milestone payments, along with tiered royalties on net sales of LX9851 [2][3] Group 3: Company Perspectives - Lexicon's CEO expressed enthusiasm about the progress made by Novo Nordisk in advancing LX9851, highlighting its potential as a differentiated treatment for obesity [4] - Novo Nordisk's Senior Vice President emphasized the novel approach of LX9851 in treating obesity and related metabolic conditions, marking it as a significant addition to their pipeline [4]

Core Points - A Jazz Aviation Mitsubishi CRJ-900 was involved in an accident upon landing at New York LaGuardia on March 22, 2026, carrying approximately 72 passengers and four crew members [1] - The pilot and first officer were confirmed killed in the accident, with Air Canada expressing condolences to the Jazz community and families [2] - Emergency services are on site, and injured passengers are being transported to local hospitals, but the exact number of injuries or additional fatalities has not been confirmed [2] - Air Canada and Jazz Aviation are cooperating with the Transportation Safety Board of Canada and the National Transportation Safety Board in the investigation of the incident [3] Company and Industry Summary - The incident involved Air Canada Express flight AC8646, operated by Jazz Aviation LP, which originated from Montréal [1] - Air Canada and Jazz are committed to providing regular updates as more information becomes available regarding the accident [3] - Family and friends seeking information about passengers can contact Air Canada directly [4]

Core Viewpoint - Jiuzi Holdings, Inc. has successfully negotiated partnerships in Vietnam, planning to deliver over 100 electric heavy-duty trucks, marking a significant step in its strategy for the Southeast Asian new energy commercial vehicle market [1][2]. Group 1: Business Developments - The company has completed important business negotiations with logistics transportation enterprises, industrial park operators, and urban logistics service providers in Vietnam, resulting in cooperation intentions for an initial order of more than 100 electric heavy-duty trucks [3]. - Jiuzi is positioning Vietnam as a strategic hub for its expansion into the Southeast Asian electric commercial vehicle market, capitalizing on the country's rapid growth and increasing demand for new energy vehicles [2][4]. Group 2: Product Features - The electric heavy-duty trucks are customized for the Southeast Asian market, featuring high-energy-density battery systems, reinforced structures for heavy-duty transport, and intelligent configurations for fleet management [4][6]. - The vehicles are designed to operate efficiently in Vietnam's tropical climate, with optimizations in battery thermal management and air conditioning systems to ensure stable performance under high temperatures and humidity [6]. Group 3: Future Outlook - Following the initial orders, Jiuzi plans to deepen its presence in Vietnam by establishing sales and after-sales service networks in key cities and collaborating with local partners to promote electric heavy trucks [4]. - The company is also exploring potential customer discussions in other Southeast Asian countries, including Indonesia, Thailand, and Malaysia, to create regional synergies and scalable business models [4][5].

Core Insights - Royalty Pharma plc has appointed Lucas Glass as Head of Artificial Intelligence, effective April 2026, to enhance its AI capabilities across the organization [1][2] - The appointment is part of Royalty Pharma's strategy to integrate advanced technology, including intelligent automation and AI-driven decision support, to improve investment evaluations and operational efficiency [2] Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical sector [3] - The company collaborates with a range of entities, from academic institutions to leading global pharmaceutical companies, and has a portfolio that includes royalties on over 35 commercial products and 19 development-stage candidates [3]

Core Insights - WeRide Inc. reported significant financial growth in 2025, with total revenue reaching RMB684.6 million (US$97.9 million), a year-over-year increase of 89.6% [24]. - The company achieved a notable milestone in its robotaxi business, expanding its global fleet to 1,125 vehicles and enhancing operational efficiency through technological advancements [4][6]. - WeRide's international operations have expanded into 12 countries, with successful deployments in key markets such as Europe and the Middle East [10][14]. Financial Highlights Fourth Quarter 2025 - Total revenue for Q4 2025 was RMB314.0 million (US$44.9 million), up 123.0% from RMB140.8 million in Q4 2024 [17]. - Product revenue surged by 308.9% year over year to RMB211.4 million (US$30.2 million), driven by increased sales of robotaxi and robobus [19]. - Gross profit for Q4 2025 was RMB89.5 million (US$12.8 million), reflecting a gross profit margin of 28.5% [19][20]. Full Year 2025 - Total revenue for the full year 2025 was RMB684.6 million (US$97.9 million), compared to RMB361.1 million in 2024 [24]. - Product revenue increased by 310.3% year over year to RMB359.8 million (US$51.5 million) [30]. - The net loss for 2025 narrowed to RMB1.7 billion (US$236.6 million), a 34.2% improvement from the previous year [29]. Operational Updates - The robotaxi business remains a key growth driver, with a 66.4% increase in robotaxi revenue to RMB50.6 million (US$7.2 million) in Q4 2025 [19]. - WeRide's global robotaxi fleet is projected to reach 2,600 vehicles by the end of 2026, with ongoing expansion in international markets [14]. - The company received the first-ever driverless robotaxi permit in Europe, establishing a first-mover advantage in the market [9]. Technology Development - WeRide has launched the WeRide GENESIS platform, enhancing AI-driven development and reducing on-road testing costs [14]. - The next-generation robotaxi GXR is set to improve safety and lower costs, with production times reduced to under 10 minutes [14]. Share Repurchase Program - The board of directors authorized a share repurchase program of up to US$100 million, effective March 23, 2026 [13].

Core Insights - Hexagon Purus ASA has entered into a financing agreement with CIMC Hydrogen Energy Technology LTD to enhance its joint venture in China, allowing CIMC Enric to increase its ownership share while minimizing Hexagon Purus' cash outflow [2][3] - The Chinese market is crucial for Hexagon Purus, being the largest global market for hydrogen-related mobility and infrastructure solutions, and the joint venture is adapting its operational model to meet current market conditions [3] Financing Agreement - CIMC Enric will provide funding for the joint venture in 2026 in exchange for a higher ownership share, which aims to reduce Hexagon Purus' cash outflow while maintaining operations in China [2] - Hexagon Purus retains the right to restore its original ownership level in the future, indicating a strategic approach to capital efficiency [2] Market Strategy - The joint venture is focused on securing certification for the Chinese market and has agreed to simplify its structure to enhance cost efficiency, execution speed, and competitiveness [3] - The operational adjustments are part of Hexagon Purus' ongoing business portfolio review, emphasizing the importance of the Chinese market for the company's growth [3]